Evidence map›Paper›PMID 38716543›Full record

ReviewAdvanced healthcare materials2025

Advanced Immunomodulatory Biomaterials for Therapeutic Applications.

Ji-Eun Park, Dong-Hwee Kim

Abstract readReview
In one paragraph

Review in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ji-Eun ParkKU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, 02841, Republic of Korea.
Dong-Hwee KimKU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, 02841, Republic of Korea.ORCID 0000-0003-0625-0660

Funding

Ministry of Science and ICT, South Korea IITP-2024-2020-0-01819National Research Foundation of Korea 2021R1A5A2022318National Research Foundation of Korea 2V10330-24-P039National Research Foundation of Korea NRF-2022M3H4A1A03067401National Research Foundation of Korea RS-2023-00221182National Research Foundation of Korea RS-2023-00251315
6 · The paper itself

Abstract

The multifaceted biological defense system modulating complex immune responses against pathogens and foreign materials plays a critical role in tissue homeostasis and disease progression. Recently developed biomaterials that can specifically regulate immune responses, nanoparticles, graphene, and functional hydrogels have contributed to the advancement of tissue engineering as well as disease treatment. The interaction between innate and adaptive immunity, collectively determining immune responses, can be regulated by mechanobiological recognition and adaptation of immune cells to the extracellular microenvironment. Therefore, applying immunomodulation to tissue regeneration and cancer therapy involves manipulating the properties of biomaterials by tailoring their composition in the context of the immune system. This review provides a comprehensive overview of how the physicochemical attributes of biomaterials determine immune responses, focusing on the physical properties that influence innate and adaptive immunity. This review also underscores the critical aspect of biomaterial-based immune engineering for the development of novel therapeutics and emphasizes the importance of understanding the biomaterials-mediated immunological mechanisms and their role in modulating the immune system.

Indexed as

Biocompatible MaterialsImmunologic FactorsImmunomodulationAdaptive ImmunityAnimalsHumansHydrogelsImmunity, InnateNanoparticlesTissue EngineeringBiocompatible MaterialsHydrogelsImmunologic Factorscancer immunotherapyimmune systemimmunomodulationmechano‐regulationtherapeuticstissue regeneration

Identifiers

PMID38716543
PMCPMC11834384

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.